In NMB, EBM, and LBM patients with all tumor lesions, the TP53 wild-type group had a higher DCR than the TP53 mutant expression group (p < 0.05), but not ORR (p > 0.05) (Table 6, Figure 5). This evidence concerns the gene TP53 and bullous dystrophy, macular type.